Simon Finfer

 
Simon Finfer is a Senior Staff Specialist in Intensive Care at Royal North Shore Hospital in Sydney and a Director of the Critical Care and Trauma Division of The George Institute for International Health. He is a Professor in the Faculty of Medicine of the University of Sydney and Honorary Associate Professor in the Department of Epidemiology and Preventative Medicine at Monash University in Melbourne. He is a past-Chair of the Australian and New Zealand Intensive Care Society Clinical Trials Group and a member of the Governing Board for the Australian and New Zealand Intensive Care Research Centre in Melbourne. His postgraduate qualifications include Fellowship of the Royal Colleges of Physicians of the United Kingdom, Fellowship of the Royal College of Anaesthetists of the United Kingdom and Fellowship of the Joint Faculty of Intensive Care Medicine of the Royal Australasian College of Physicians and Australian and New Zealand College of Anaesthetists. 

Professor Finfer's major academic interest is the design and conduct of large scale randomised controlled trials in critical care. He was the lead investigator for the 6997 patient SAFE study (N Engl J Med 2004 May 27;350:2247-56) and is the lead investigator and study Chair for the 6100 patient NICE-SUGAR study.
 
Competing interests statement:
Professor Finfer has received research funding and travel support from CSL Bioplasma and Eli Lilly. Professor Finfer is a member of the steering committees for the PROWESS-SHOCK Trial (Lilly) and the ACCESS Trial (Eisai Ltd.).
Professor Finfer does not accept payments from pharmaceutical companies, all honoraria and consulting fees are paid to his employing institutions’ research funds.